ImmuCell Announces Onboarding of New CEO and Related Management Changes

Core Insights - ImmuCell Corporation has appointed Olivier te Boekhorst as the new President and CEO effective November 1, 2025, succeeding Michael F. Brigham [2][3] - The company is focused on enhancing its First Defense franchise and completing the development of Re-Tain, a treatment for subclinical mastitis in dairy cows [3][4] Leadership Changes - Olivier te Boekhorst has taken over as President and CEO, with Michael F. Brigham continuing as a Board member and Special Advisor until January 2026 [2] - Timothy C. Fiori has been appointed as CFO, bringing 24 years of experience in the livestock industry, and will also serve as Treasurer and Secretary [2] Upcoming Financial Discussion - ImmuCell plans to host a conference call on November 14, 2025, to discuss the unaudited financial results for the quarter ended September 30, 2025 [3] - Investors can access the call via specific phone numbers and a replay will be available until November 21, 2025 [3] Company Overview - ImmuCell develops and markets products aimed at improving the health and productivity of dairy and beef cattle, including the First Defense product line [4] - The company is in the late stages of developing Re-Tain, which offers an alternative to traditional antibiotics without FDA-required milk discard or pre-slaughter withdrawal restrictions [4]